On Wednesday, LiveDeal Inc. (NASDAQ:LIVE)’s stock gained 33.77% and closed at $5.07, gaining the top position among NASDAQ stocks posting “Largest Percentage Increases.” The stock traded with significant volume of nearly 16 million shares as compared to its 30 day average trading volume of 1.6 million shares. During the session, the stock marked an intraday high of $5.34. The stock has gained more than 65% over past five trading sessions and yet it is 35% down if we consider the price difference over past three months. LiveDeal’s market capitalization increased to $68.87 million with total 13.58 million shares outstanding. LiveDeal Inc (NASDAQ:LIVE) net profit margin is (not available) % and weekly performance is 96.22%. On last trading day company shares ended up $ 4.67. Analysts mean target price for the company is $ 1.50. LiveDeal Inc (NASDAQ:LIVE) distance from 50-day simple moving average (SMA50) is -8.72%.
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC)’s shares gained 2.59% to $1.39. The company on May 8 announced financial results for the quarter ended March 31, 2014. For the quarter ended March 31, 2014, the Company incurred a net loss of $3.2 million, or $0.05 per basic and diluted share, compared to a net loss of $5.0 million, or $0.10 per basic and diluted share for the quarter ended March 31, 2013. The Company reported that cash used in operations during the first quarter of 2014 was $2.6 million compared to $2.2 million during the first quarter of 2013. ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) shares fell -0.74% in last trading session and ended the day on $ 1.34. {IMUC} Gross Margin is (not available) % and its return on assets is -25.50%. ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) quarterly performance is -1.47 %.
GTX Inc. (NASDAQ:GTXI) was a big mover last session, as its shares rose nearly 10% on the day. The rise came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend for the company, as the stock now trading above the volatile price range of $1.31 to $1.54 in the past one-month timeframe. GTx, Inc. (NASDAQ:GTXI) shares moved up 1.22% in last trading session and was closed at $ 1.66, while trading in range of $ 1.55 – $ 1.70. GTx, Inc.(NASDAQ:GTXI) year to date (YTD) performance is 0.61%.
CytRx Corporation (NASDAQ:CYTR)’s shares declined 3.63% to $3.98. The company on May 28 announced updated results from its ongoing multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas (STS). The updated trial results demonstrated that aldoxorubicin significantly increases progression-free survival (PFS), PFS at 6 months, overall response rate (ORR) and tumor shrinkage, compared to doxorubicin, the current standard-of-care, as a first-line treatment in patients with STS. The data trended in favor of aldoxorubicin for all of the major subtypes of soft tissue sarcomas. The results will be presented by Sant P. Chawla, M.D., F.R.A.C.P., Director of the Sarcoma Oncology Center, and principal investigator of the trial, in an oral presentation at the 2014 American Society for Clinical Oncology (ASCO) Annual Meeting, which is taking place May 30–June 3 in Chicago. CytRx Corporation (NASDAQ:CYTR) ended the last trading day at $ 0.61. Company weekly volatility is calculated as 7.71% and price to cash ratio as 6.04. CytRx Corporation (NASDAQ:CYTR) showed a positive weekly performance of 15.47%.
Galena Biopharma Inc (NASDAQ:GALE)’s shares jumped 2.06% to $2.48. The company on May 21 announced that data from the Company’s Phase 1 study with GALE-301, or Folate Binding Protein, will be presented at the upcoming American Society of Clinical Oncology (ASCO) 50th Annual Meeting. Abstract #5559 is entitled, “Comparison of recurrent and nonrecurrent ovarian and uterine cancer patients undergoing adjuvant folate receptor vaccine therapy.” Galena Biopharma Inc (NASDAQ:GALE) net profit margin is (not available)% and weekly performance is 6.48%. On last trading day company shares ended up $ 2.30. Analysts mean target price for the company is $ 6.88. Galena Biopharma Inc (NASDAQ:GALE) distance from 50-day simple moving average (SMA50) is -1.47%.
Leave a Reply